This article provides a comprehensive comparison for researchers and drug development professionals between traditional cancer diagnostics and emerging artificial intelligence (AI)-based approaches.
The translation of artificial intelligence (AI) models from promising research tools to reliable clinical assets hinges on robust validation across diverse, multi-center datasets.
This article provides a systematic review of the current landscape, methodologies, and challenges in benchmarking foundation models for cancer imaging.
The integration of artificial intelligence and machine learning into drug development promises to revolutionize the industry by accelerating discovery and optimizing clinical trials.
This article explores the transformative potential of self-supervised learning (SSL) to overcome the critical challenge of data scarcity in drug discovery and development.
This article examines the critical challenge of false positives in cancer screening and explores the transformative role of Artificial Intelligence (AI) in addressing this issue.
This article provides a comprehensive exploration of multimodal data fusion and its transformative impact on cancer diagnosis and personalized oncology.
This article provides a comprehensive guide for researchers and drug development professionals on ensuring machine learning models perform reliably amidst real-world data variations.
Class imbalance, where one class (e.g., healthy samples) significantly outnumbers another (e.g., cancerous samples), is a pervasive challenge that severely biases machine learning models in oncology.
This article provides a comprehensive analysis of automated tumor segmentation using deep learning, tailored for researchers and drug development professionals.